Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis

Nature Reviews Drug Discovery

Volumn 15, Issue 2, 2016, Pages 125-142

  Kreuger, Johan ^a   Phillipson, Mia ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABRILUMAB; AFLIBERCEPT; BETA CATENIN; BEVACIZUMAB; CONNEXIN 43; EFALIZUMAB; ETROLIZUMAB; FRIZZLED PROTEIN; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NATALIZUMAB; NI 0101; NINTEDANIB; PHOSPHOLIPASE C GAMMA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TRANSCRIPTION FACTOR SOX17; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VEDOLIZUMAB; WNT PROTEIN; GROWTH INHIBITOR;

AGE RELATED MACULAR DEGENERATION; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTIINFLAMMATORY ACTIVITY; BLOOD FLOW; BLOOD VESSEL PERMEABILITY; CELL ADHESION; CELL COMMUNICATION; CELL INTERACTION; CELL METABOLISM; CELL POPULATION; CELL SPREADING; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG TARGETING; ENDOTHELIUM CELL; EXOSOME; FIBROSING ALVEOLITIS; FIBROSIS; GLYCOLYSIS; HUMAN; INFLAMMATION; KIDNEY CARCINOMA; LEUKOCYTE; LEUKOCYTE MIGRATION; MACROPHAGE; MACROPHAGE ACTIVATION; METASTATIC COLORECTAL CANCER; MULTIPLE SCLEROSIS; NONHUMAN; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; PSORIASIS; REVIEW; TISSUE REGENERATION; ULCERATIVE COLITIS; WET MACULAR DEGENERATION; ANIMAL; CAPILLARY PERMEABILITY; CYTOLOGY; DRUG EFFECTS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; CAPILLARY PERMEABILITY; CELL COMMUNICATION; ENDOTHELIUM, VASCULAR; FIBROSIS; GROWTH INHIBITORS; HUMANS; INFLAMMATION; LEUKOCYTES; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84957850416     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2015.2     Document Type: Review

References (246)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971
2. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650-1659 (1986
3. Casazza A., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695-709 (2013
4. Christoffersson G., et al. VEGF A recruits a proangiogenic MMP 9 delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue. Blood 120, 4653-4662 (2012
5. Chung A. S., et al. An interleukin 17 mediated paracrine network promotes tumor resistance to anti-ngiogenic therapy. Nat. Med. 19, 1114-1123 (2013
6. Ehling J., et al. CCL2 dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 63, 1960-1971 (2014
7. Kolaczkowska, E., & Kubes, P. Neutrophil recruitment and function in health and inflammation. Nat. Rev. Immunol. 13, 159-175 (2013
8. Stark K., et al. Capillary and arteriolar pericytes attract innate leukocytes exiting through venules and instruct them with pattern-recognition and motility programs. Nat. Immunol. 14, 41-51 (2013
9. Hase K., et al. M Sec promotes membrane nanotube formation by interacting with Ral and the exocyst complex. Nat. Cell Biol. 11, 1427-1432 (2009
10. Kristensen V. N., et al. Principles and methods of integrative genomic analyses in cancer. Nat. Rev. Cancer 14, 299-313 (2014
11. Islam S., et al. Quantitative single-cell RNA-seq with unique molecular identifiers. Nat. Meth. 11, 163-166 (2014
12. Bentley K., et al. The role of differential VE cadherin dynamics in cell rearrangement during angiogenesis. Nat. Cell Biol. 16, 309-321 (2014
13. Dejana, E., Tournier-Lasserve, E., & Weinstein, B. M. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev. Cell 16, 209-221 (2009
14. Chauhan, V. P., Stylianopoulos, T., Boucher, Y., & Jain, R. K. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu. Rev. Chem. Biomol. Eng. 2, 281-298 (2011
15. Heldin, C. H., Rubin, K., Pietras, K., & Ostman, A. High interstitial fluid pressure-n obstacle in cancer therapy. Nat. Rev. Cancer 4, 806-813 (2004
16. Conway D. E., et al. Fluid shear stress on endothelial cells modulates mechanical tension across VE cadherin and PECAM 1. Curr. Biol. 23, 1024-1030 (2013
17. Tzima, E., et al. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 437 426-431 2005
18. Langenkamp, E., & Molema, G. Microvascular endothelial cell heterogeneity: general concepts and pharmacological consequences for anti-ngiogenic therapy of cancer. Cell Tissue Res. 335, 205-222 (2009
19. Swift, M. R., & Weinstein, B. M. Arterial-venous specification during development. Circ. Res. 104, 576-588 (2009
20. Lawson, N. D., Vogel, A. M., & Weinstein, B. M. Sonic hedgehog and vascular endothelial growth factor act upstream of the Notch pathway during arterial endothelial differentiation. Dev. Cell 3, 127-136 (2002
21. Wang, H. U., Chen, Z. F., & Anderson, D. J. Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin B2 and its receptor Eph B4. Cell 93, 741-753 (1998
22. D Onofrio N., et al. Vascular-homing peptides for targeted drug delivery and molecular imaging: meeting the clinical challenges. Biochim. Biophys. Acta 1846, 1-12 (2014
23. Ageirsdottir S. A., et al. Site-specific inhibition of glomerulonephritis progression by targeted delivery of dexamethasone to glomerular endothelium. Mol. Pharmacol. 72, 121-131 (2007
24. Ageirsdottir, S. A., et al. Inhibition of proinflammatory genes in anti GB; glomerulonephritis by targeted dexamethasone-loaded AbEsel liposomes. Am. J. Renal Physiol. 294, F554-F561 (2008
25. Corada M., et al. Sox17 is indispensable for acquisition and maintenance of arterial identity. Nat. Commun. 4, 2609 (2013
26. Fancy S. P., et al. Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer. Nat. Neurosci. 17, 506-512 (2014
27. Wu, B., Crampton, S. P., & Hughes, C. C. Wnt signaling induces matrix metalloproteinase expression and regulates T cell migration. Immunity 26, 227-239 (2007
28. Jung, Y. S., et al. Wnt5a stimulates chemotactic migration and chemokine production in human neutrophils. Exp. Mol. Med. 45, e27 (2013
29. Maiti, G., Naskar, D., & Sen, M. The Wingless homolog Wnt5a stimulates phagocytosis but not bacterial killing. Proc. Natl Acad. Sci. USA 109, 16600-16605 (2012
30. Armulik A., et al. Pericytes regulate the blood-brain barrier. Nature 468, 557-561 (2010
31. Gaengel K., et al. The sphingosine 1 phosphate receptor S1PR1 restricts sprouting angiogenesis by regulating the interplay between VE cadherin and VEGFR2. Dev. Cell 23, 587-599 (2012
32. Krueger, M., & Bechmann, I. CNS pericytes: concepts, misconceptions, and a way out. Glia 58, 1-10 (2010
33. Sims, D. E. The pericyte- review. Tissue Cell 18, 153-174 (1986
34. Sims, D. E. Recent advances in pericyte biology-implications for health and disease. Can. J. Cardiol. 7, 431-443 (1991
35. Falcón B. L., et al. Contrasting actions of selective inhibitors of angiopoietin 1 and angiopoietin 2 on the normalization of tumor blood vessels. Am. J. Pathol. 175, 2159-2170 (2009
36. Gerhardt, H., Wolburg, H., & Redies, C. N cadherin mediates pericytic-endothelial interaction during brain angiogenesis in the chicken. Dev. Dyn. 218, 472-479 (2000
37. Wernersson, S., & Pejler, G. Mast cell secretory granules: armed for battle. Nat. Rev. Immunol. 14, 478-494 (2014
38. Pollard, A. J., Perrett, K. P., & Beverley, P. C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9, 213-220 (2009
39. Fantin A., et al. Tissue macrophages act as cellular chaperones for vascular anastomosis downstream of VEGF-mediated endothelial tip cell induction. Blood 116, 829-840 (2010
40. Sica, A., & Mantovani, A. Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787-795 (2012
41. Mantovani, A. Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10, 369-373 (2010
42. Mantovani, A., & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010
43. Nozawa, H., Chiu, C., & Hanahan, D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. Proc. Natl Acad. Sci. USA 103, 12493-12498 (2006
44. Wynn, T. A., Chawla, A., & Pollard, J. W. Macrophage biology and health and disease. Nature 496, 445-455 (2013
45. Gautier E. L., et al. Gene-expression profiles and transcriptional regulatory pathways that underlie the identity and diversity of mouse tissue macrophages. Nat. Immunol. 13, 1118-1128 (2012
46. Armulik, A., Genové, G., & Betsholtz, C. Pericytes: development, physiological, and pathological perspectives, problems, and promises. Dev. Cell 21, 193-215 (2011
47. Wei X., et al. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol. Sin. 34, 747-754 (2013
48. Leeper, N. J., Hunter, A. L., & Cooke, J. P. Stem cell therapy for vascular regeneration. Circulation 122, 517-526 (2010
49. Schinköthe, T., Bloch, W., & Schmidt, A. In vitro secreting profile of human mesenchymal stem cells. Stem Cells Dev. 17, 199-206 (2008
50. Hsiao, S. T., et al. Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose tissue, and dermal tissue. Stem Cells Dev. 21, 2189-2203 (2012
51. Rustad, K. C., & Gurtner, G. C. Mesenchymal stem cells home to sites of injury and inflammation. Adv. Wound Care 1, 147-152 (2012
52. Abram, C. L., & Lowell, C. A. The ins and outs of leukocyte integrin signaling. Annu. Rev. Immunol. 27, 339-362 (2009
53. Fang, J. S., Dai, C., Kurjiaka, D. T., Burt, J. M., & Hirschi, K. K. Connexin45 regulates endothelial-induced mesenchymal cell differentiation toward a mural cell phenotype. Arterioscler. Thromb. Vasc. Biol. 33, 362-368 (2013
54. Hirschi, K. K., Burt, J. M., Hirschi, K. D., & Dai, C. Gap junction communication mediates transforming growth factor-β activation and endothelial-induced mural cell differentiation. Circ. Res. 93, 429-437 (2003
55. Westphalen K., et al. Sessile alveolar macrophages communicate with alveolar epithelium to modulate immunity. Nature 506, 503-506 (2014
56. Mazzini, E., Massimiliano, L., Penna, G., & Rescigno, M. Oral tolerance can be established via gap junction transfer of fed antigens from CX3CR1+ macrophages to CD103+ dendritic cells. Immunity 40, 248-261 (2014
57. Oviedo-Orta, E., Errington, R. J., & Evans, W. H. Gap junction intercellular communication during lymphocyte transendothelial migration. Cell. Biol. Int. 26, 253-263 (2002
58. Zahler S., et al. Gap-junctional coupling between neutrophils and endothelial cells: a novel modulator of transendothelial migration. J. Leuk. Biol. 73, 118-126 (2003
59. Ghatnekar G. S., et al. Connexin43 carboxyl-Terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding. Regen. Med. 4, 205-223 (2009
60. Grek, C. S., Rhett, J. M., & Ghatnekar, G. S. Cardiac to cancer: connecting connexins to clinical opportunity. FEBS Lett. 588, 1349-1364 (2014
61. Ghatnekar, G. S., Grek, C. L., Armstrong, D. G., Desai, S. C., & Gourdie, R. G. The effect of a connexin43 based peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial. J. Invest. Dermatol. 135, 289-298 (2015
62. van Balkom B. W., et al. Endothelial cells require miR 214 to secrete exosomes that suppress senescence and induce angiogenesis in human and mouse endothelial cells. Blood 121, 3997-4006 (2013
63. Valadi H., et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654-659 (2007
64. Patzelt, J., & Langer, H. F. Platelets in angiogenesis. Curr. Vasc. Pharmacol. 10, 570-577 (2012
65. Sreeramkumar V., et al. Neutrophils scan for activated platelets to initiate inflammation. Science 346, 1234-1238 (2014
66. Battinelli, E. M., Markens, B. A., & Italiano, J. E. Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 118, 1359-1369 (2011
67. Alvarez-Erviti L., et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotech. 29, 341-345 (2011
68. Zech, D., Sanyukta, R., B?chler, M. W., & X?ller, M. Tumor-crosstalk and leukocyte activation: an ambivalent crosstalk. Cell Comm. Signal. 10, 37 (2012
69. Marleau, A. M., Chen, C. S., Joyce, J. A., & Tullis, R. H. Exosome removal as a therapeutic adjuvant in cancer. J. Transl. Med. 10, 134 (2012
70. Lu H., et al. Exo70 isoform switching upon epithelial-mesenchymal transition mediates cancer cell invasion. Dev. Cell 27, 560-573 (2013
71. Zhao Y., et al. Exo70 generates membrane curvature for morphogenesis and cell migration. Dev. Cell 26, 266-278 (2013
72. Chacon-Heszele, M. F., et al. The exocyst and regulatory GTPases in urinary exosomes. Physiol. Rep. 2, e12116 (2014
73. Lou, E., et al. Tunneling nanotubes provide a unique conduit for intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS ONE 7, e33093 (2012
74. Ahmad T., et al. Miro1 regulates intercellular mitochondrial transport and enhances mesenchymal stem cell rescue efficacy. EMBO J. 33, 994-1010 (2014
75. Chen, L., Yang, S., Jakoncic, J., Zhang, J. J., & Huang, X. Y. Migrastatin analogues target fascin to block tumour metastasis. Nature 464, 1062-1066 (2010
76. Pasquier J., et al. Preferential transfer of mitochondria from endothelial to cancer cells through tunneling nanotubes modulates chemoresistance. J. Transl. Med. 11, 94 (2013
77. Rainy, N., et al. H Ras transfers from B to T cells via tunneling nanotubes. Cell Death Dis 4, e726 (2013
78. Yasuda K., et al. Tunneling nanotubes mediate rescue of prematurely senescent endothelial cells by endothelial progenitors: exchange of lysosomal pool. Aging 3, 597-608 (2011
79. Liu K., et al. Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemia-reperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer. Microvasc. Res. 92, 10-18 (2014
80. Claesson-Welsh, L., & Welsh, M. VEGFA and tumour angiogenesis. J. Intern. Med. 273, 114-127 (2013
81. Jain, R. K. Normalizing tumor vasculature with anti-ngiogenic therapy: a new paradigm for combination therapy. Nat. Med. 7, 987-989 (2001
82. Adams, R. H., & Alitalo, K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat. Rev. Mol. Cell. Biol. 8, 464-478 (2007
83. Styp-Rekowska, B., Hlushchuk, R., Pries, A. R., & Djonov, V. Intussusceptive angiogenesis: pillars against the blood flow. Acta Physiol. (Oxf.) 202, 213-223 (2011
84. Adams, R. H., & Eichmann, A. Axon guidance molecules in vascular patterning. Cold Spring Harb. Perspect. Biol. 2, a001875 (2010
85. Jakobsson, L., Kreuger, J., & Claesson-Welsh, L. Building blood vessels-stem cell models in vascular biology. J. Cell Biol. 177, 751-755 (2007
86. Lander, A. D. How cells know where they are. Science 339, 923-927 (2013
87. Benest, A. V., & Augustin, H. G. Tension in the vasculature. Nat. Med. 15, 608-610 (2009
88. Boerckel, J. D., Uhrig, B. A., Willett, N. J., Huebsch, N., & Guldberg, R. E. Mechanical regulation of vascular growth and tissue regeneration in vivo. Proc. Natl Acad. Sci. USA 108, E674-E680 (2011
89. Kilarski, W. W., Samolov, B., Petersson, L., Kvanta, A., & Gerwins, P. Biomechanical regulation of blood vessel growth during tissue vascularization. Nat. Med. 15, 657-664 (2009
90. Vakoc B. J., et al. Three-dimensional microscopy of the tumor microenvironment in vivo using optical frequency domain imaging. Nat. Med. 15, 1219-1223 (2009
91. Tabe, Y., et al. TGF β neutralizing antibody 1D11 enhances cytarabine-induced apoptosis in AML cells in the bone marrow microenvironment. PLoS ONE 8, e62785 (2011
92. Dituri, F., et al. Differential inhibition of the TGF β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF β receptor type II. PLoS ONE 8, e67109 (2013
93. Santiago B., et al. Topical application of a peptide inhibitor of transforming growth factor β1 ameliorates bleomycin-induced skin fibrosis. J. Invest. Dermatol. 125, 450-455 (2005
94. Khalil, N., Bereznay, O., Sporn, M., & Greenberg, A. H. Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. J. Exp. Med. 170, 727-737 (1989
95. Nacu N., et al. Macrophages produce TGF-β-induced (β ig h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J. Immunol. 180, 5036-5044 (2008
96. Taichman, N. S., Young, S., Cruchley, A. T., Taylor, P., & Paleoplog, E. Human neutrophils secrete vascular endothelial growth factor. J. Leuk. Biol. 62, 397-400 (1997
97. Auffray C., et al. Monitoring of blood vessels and tissue by a population of monocytes with patrolling behavior. Science 317, 666-670 (2007
98. Awojoodu A. O., et al. Sphingosine 1 phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. Proc. Natl Acad. Sci. USA 110, 13785-13790 (2013
99. Carlin L. M., et al. Nr4a1 dependent Ly6C(low) monocytes monitor endothelial cells and orchestrate their disposal. Cell 153, 362-375 (2013
100. Ganju, R. K., et al. The α-chemokine, stromal cell-derived factor 1α, binds to the transmembrane G protein-coupled CXCR 4 receptor and activates multiple signal transduction pathways. J. Biol. Chem. 273, 23169-23175 (1998
101. Grunewald, M., et al. VEGF-induced adult neovascuarisation, recruitment, retention and role of accessory cells. Cell 124, 175-189 (2006
102. Avraham-Davidi I., et al. On site education of VEGF-recruited monocytes improves their performance as angiogenesis and arteriogenic accessory cells. J. Exp. Med. 210, 2611-2625 (2013
103. Christoffersson G., et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes 59, 2569-2578 (2010
104. Massena, S., et al. Identification and characterization of VEGF-responsive neutrophils expressing CD49d, VEGFR1 and CXCR4 in mice and humans. Blood 126, 2016-2026 (2015
105. Kerbel, R. S. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 13, 31-36 (1991
106. Lim, L. S., Mitchell, P., Seddon, J. M., Holz, F. G., & Wong, T. Y. Age-related macular degeneration. Lancet 379, 1728-1738 (2012
107. Reck M., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J. Clin. Oncol. 27, 1227-1234 (2009
108. Saltz L. B., et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol. 26, 2013-2019 (2008
109. Sandler A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355, 2542-2550 (2006
110. Willett C. G., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human renal cancer. Nat. Med. 10, 145-147 (2004
111. Batchelor T. T., et al. Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl Acad. Sci. USA 47, 19059-19064 (2013
112. Armstrong, T. S., Wen, P. Y., Gilbert, M. R., & Schiff, D. Management of treatment-ssociated toxicites of anti-ngiogenic therapy in patients with brain tumors. Neuro. Oncol. 14, 1203-1214 (2012
113. Wu, J. M., & Staton, C. A. Anti-ngiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opin. Drug Discov. 7, 723-743 (2012
114. Bergers, G., & Hanahan, D. Modes of resistance to anti-ngiogenic therapy. Nat. Rev. Cancer 8, 592-603 (2008
115. Barone A., et al. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma. Oncotarget 5, 9811-9822 (2014
116. Hassan, S., et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer 129, 225-232 (2011
117. Pan Q., et al. Blocking neuropilin 1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11, 53-67 (2007
118. Ruan, G. X., & Kazlauskas, A. Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3 kinase/Akt and promote angiogenesis. J. Biol. Chem. 288, 21161-21172 (2013
119. De Bock K., et al. Role of PFKFB3 driven glycolysis in vessel sprouting. Cell 154, 651-663 (2013
120. Leopold J. A., et al. Glucose 6 phosphate dehydrogenase modulates vascular endothelial growth factor-mediated angiogenesis. J. Biol. Chem. 278, 32100-32106 (2003
121. Schoors S., et al. Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological angiogenesis. Cell. Metab. 19, 37-48 (2014
122. Leite de Oliveira R., et al. Gene-Targeting of Phd2 improves tumor response to chemotherapy and prevents side-Toxicity. Cancer Cell 22, 263-277 (2012
123. Mazzone M., et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 136, 839-851 (2009
124. Takeda Y., et al. Macrophage skewing by Phd2 haplodeficiency prevents ischaemia by inducing arteriogenesis. Nature 479, 122-126 (2011
125. Hamm A., et al. PHD2 regulates arteriogenic macrophages through TIE2 signalling. EMBO Mol. Med. 5, 843-857 (2013
126. Flagg, S. C., Martin, C. B., Taabazuing, C. Y., Holmes, B. E., & Knapp, M. J. Screening chelating inhibitors of HIF-prolyl hydroxylase domain 2 (PHD2) and factor inhibiting HIF (FIH). J. Inorg. Biochem. 113, 25-30 (2012
127. Hellström M., et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445, 776-780 (2007
128. Phng L. K., et al. Nrarp coordinates endothelial Notch and Wnt signaling to control vessel density in angiogenesis. Dev. Cell 16, 70-82 (2009
129. Dimova I., et al. Inhibition of Notch signaling induces extensive intussusceptive neo-ngiogenesis by recruitment of mononuclear cells. Angiogenesis 16, 921-937 (2013
130. Outtz, H. H., Tattersall, I. W., Kofler, N. M., Steinbach, N., & Kitajewski, J. Notch1 controls macrophage recruitment and Notch signaling is activated at sites of endothelial cell anastomosis during retinal angiogenesis in mice. Blood 118, 3436-3439 (2011
131. Camelo S., et al. Delta-like 4 inhibits choroidal neovascularization despite opposing effects on vascular endothelium and macrophages. Angiogenesis 15, 609-622 (2012
132. Haj Zen A. A., et al. Inhibition of delta-like 4-mediated signaling impairs reparative angiogenesis after ischemia. Circ. Res. 107, 283-293 (2010
133. Wang Y. C., et al. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res. 70, 4840-4849 (2010
134. Xu H., et al. Notch-RBP J signaling regulates the transcription factor IRF8 to promote inflammatory macrophage polarization. Nat. Immunol. 13, 642-650 (2012
135. Stockmann C., et al. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456, 814-819 (2008
136. DeNardo D. G., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54-67 (2011
137. Ries C. H., et al. Targeting tumor-ssociated macrophages with anti-CSF 1R antibody reveals a strategy for cancer therapy. Cancer Cell 25, 846-859 (2014
138. Bonapace L., et al. Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130-133 (2014
139. Stefater, J. A. 3rd et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474, 511-515 (2011
140. Stefater, J. A. 3rd et al. Macrophage Wnt-Calcineurin-Flt1 signaling regulates mouse wound angiogenesis and repair. Blood 121, 2574-2578 (2013
141. Ross, K. For organ transplant recipients, cancer threatens long-Term survival. J. Nat. Cancer Inst. 99, 421-422 (2007
142. Ley, K., Laudanna, C., Cybulsky, M. I., & Nourshargh, S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 7, 678-689 (2007
143. Nourshargh, S., Hordijk, P. L., & Sixt, M. Breaching multiple barriers: leukocyte motility through venular walls and the interstitium. Nat. Rev. Mol. Cell. Biol. 11, 366-378 (2010
144. Phillipson, M., & Kubes, P. The neutrophil in vascular inflammation. Nat. Med. 17, 1381-1390 (2011
145. Luo, B. H., Carman, C. V., & Springer, T. A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 25, 619-647 (2007
146. Massena, S., et al. A chemotactic gradient sequestered on endothelial heparan sulfate induces directional intraluminal crawling of neutrophils. Blood 116 1924-1931 2010
147. Phillipson M., et al. Intraluminal crawling of neutrophils to emigration sites: a molecularly distinct process from adhesion in the recruitment cascade. J. Exp. Med. 203, 2569-2575 (2006
148. Schenkel, A. R., Mamdouh, Z., & Muller, W. A. Locomotion of monocytes on endothelium is a critical step during extravasation. Nat. Immunol. 5, 393-400 (2004
149. Voisin, M. B., Pröbstl, D., & Nourshargh, S. Venular basement membranes ubiquitously express matrix protein low-expression regions: characterization in multiple tissues and remodeling during inflammation. Am. J. Pathol. 176, 482-495 (2010
150. Wang S., et al. Venular basement membranes contain specific matrix protein low expression regions that act as exit points for emigrating neutrophils. J. Exp. Med. 203, 1519-1532 (2006
151. Carman, C. V., & Springer, T. A. A transmigratory cup in leukocyte diapedesis both through individual vascular endothelial cells and between them. J. Cell Biol. 167 377-388 2004
152. Petri, B., et al. Endothelial LSP1 is involved in endothelial dome formation, minimizing vascular permeability changes during neutrophil transmigration in vivo. Blood 117, 942-952 (2011
153. Phillipson, M., Kaur, J., Colarusso, P., Ballantyne, C. M., & Kubes, P. Endothelial domes encapsulate adherent neutrophils and minimize increases in vascular permeability in paracellular and transcellular emigration. PLoS ONE 3, e1649 (2008
154. Liu L., et al. LSP1 is an endothelial gatekeeper of leukocyte transendothelial migration. J. Exp. Med. 201, 409-418 (2005
155. Broermann A., et al. Dissociation of VE PTP from VE cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. J. Exp. Med. 208, 2393-2401 (2011
156. Finsterbusch, M., Voisin, M. B., Beyrau, M., Williams, T. J., & Nourshargh, S. Neutrophils recruited by chemoattractants in vivo induce microvascular plasma protein leakage through secretion of TNF. J. Exp. Med. 211, 1307-1314 (2014
157. Proebstl D., et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. J. Exp. Med. 209, 1219-1234 (2012
158. Abtin A., et al. Perivascular macrophages mediate neutrophil recruitment during bacterial skin infection. Nat. Immunol. 15, 45-53 (2014
159. Tabas, I., & Glass, C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339, 166-172 (2013
160. Fox, D. A. Kinase inhibition- new approach to the treatment of rheumatoid arthritis. N. Engl. J. Med. 367, 565-567 (2012
161. Hoepner, R., Faissner, S., Salmen, A., Gold, R., & Chan, A. Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis. J. Cent. Nerv. Syst. Dis. 6, 41-49 (2014
162. Kothary N., et al. Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients. J. Am. Acad. Dermatol. 65, 546-551 (2011
163. Schwab N., et al. Fatal PML associated with efalizumab therapy: insights into integrin αLβ2 in JC virus control. Neurology 78, 458-467 (2012
164. Van Assche G., et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn s disease. N. Engl. J. Med. 353, 362-368 (2005
165. Feagan B. G., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Eng. J. Med. 369, 699-710 (2013
166. Sandborn W. J., et al. Vedolizumab as induction and maintenance therapy for Crohn s disease. N. Eng. J. Med. 369, 711-721 (2013
167. Briskin M., et al. Human mucosal addressin cell adhesion molecule 1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151, 97-110 (1997
168. Danese, S., & Pan?s, J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 147, 981-989 (2014
169. Fedyk E. R., et al. Exclusive antagonism of the α4β7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm. Bowel. Dis. 18, 2107-2119 (2012
170. Haanstra, K. G., et al. Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J. Immunol. 190, 1961-1973 (2013
171. Milch, C., et al. Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T lymphocyte immunophenotype. J. Neuroimmunol. 264, 123-126 (2013
172. Watanabe, M., et al. 370 AJM300, an oral α4 integrin antagonist, for active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled Phase 2A study. Gastroenterology 146, S-82 (2014
173. Economides, A. N., et al. Cytokine traps: multi-component, high-ffinity blockers of cytokine action. Nat. Med. 9, 47-52 (2003
174. Blanchetot C., et al. Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function. J. Biol. Chem. 288, 25173-25182 (2013
175. Berghmans N., et al. Rescue from acute neuroinflammation by pharmacological chemokine-mediated deviation of leukocytes. J. Neuroinfl. 9, 243 (2012
176. Li, S., et al. Interference with glycosaminoglycan-chemokine interactions with a probe to alter leukocyte recruitment and inflammation in vivo. PLoS ONE 9, e104107 (2014
177. Klarenbeek A., et al. Targeting chemokines and chemokine receptors with antibodies. Drug Discov. Today Tech. 9, 237-244 (2012
178. Perry, C. M. Maraviroc: a review of its use in the management of CCR5 tropic HIV 1 infection. Drugs 70, 1189-1213 (2010
179. De Clercq, E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem. Pharmacol. 77, 1655-1664 (2009
180. Moelants E. A., et al. Citrullination of TNF α by peptidylarginine deiminases reduces its capacity to stimulate the production of inflammatory chemokines. Cytokine 61, 161-167 (2013
181. Proost, P., et al. Citrullination of CXCL8 by peptidylarginine deiminase alters receptor usage, prevents proteolysis, and dampens tissue inflammation. J. Exp. Med. 205, 2085-2097 (2008
182. Moelants E. A., et al. Citrullination and proteolytic processing of chemokines by Porphyromonas gingivalis. Infect. Immun. 82, 2511-2519 (2014
183. Mantovani, A., Biswas, S. K., Galdiero, M. R., Sica, A., & Locati, M. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 229, 176-185 (2013
184. Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M., & Bratton, D. L. Modulation of macrophage efferocytosis in inflammation. Front. Immunol. 2, 57 (2011
185. Markworth, J. F., et al. Human inflammatory and resolving lipid mediator responses to resistance exercise and ibuprofen treatment. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R1281-R1296 (2013
186. Colas, R. A., Shinohara, M., Dalli, J., Chiang, N., & Serhan, C. N. Identification and signature profiles for pro-resolving and inflammatory lipid mediators in human tissue. Am. J. Physiol. Cell Physiol. 307, C39-C54 (2014
187. Serhan, C. N. Pro-resolving lipid mediators are leads for resolution physiology. Nature 510, 92-101 (2014
188. Jin Y., et al. Anti-ngiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Invest. Ophthalmol. Vis. Sci. 50, 4743-4752 (2009
189. Rajasagi N. K., et al. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. J. Immunol. 186, 1735-1746 (2011
190. Tang Y., et al. Proresolution therapy for the treatment of delayed healing of diabetic wounds. Diabetes 62, 618-627 (2013
191. Wu, S. H., Chen, X. Q., Liu, B., Wu, H. J., & Dong, L. Efficacy and safety of 15(R/S)-methyl-lipoxin A4 in topical treatment of infantile eczema. Br. J. Dermatol. 168, 172-178 (2013
192. Robertson A. L., et al. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci. Transl. Med. 6, 225ra29 (2014
193. Pellicoro, A., Ramachandran, P., Iredale, J. P., & Fallowfield, J. A. Liver fibrosis and repair: immune regulation of wound heling in solid organs. Nat. Rev. Immunol. 14, 181-194 (2014
194. Moustakas, A., & Heldin, P. TGFβ and matrix regulated epithelial to mesenchymal transition. Biochim. Biophys. Acta 1840, 2621-2634 (2014
195. Brenner, D. A., et al. Origin of myofibroblasts in liver fibrosis. Fibrogen. Tissue Repair 5, S17 (2012
196. Hinz, B., et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816 (2007
197. Henderson N. C., et al. Targeting of αV integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617-1624 (2013
198. Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890 (2009
199. Cenik, B. K., Ostapoff, K. T., Gerber, D. E., & Brekken, R. A. BIBF 1120 (nintedanib), a triple angiokinase inhibitor, induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer. Mol. Cancer Ther. 12, 992-1001 (2013
200. Mehal, W. Z., Iredale, J., & Friedman, S. L. Scraping fibrosis: expressway to the core of fibrosis. Nat. Med. 17, 552-553 (2011
201. Seki E., et al. TLR4 enhances TGF β signaling and hepatic fibrosis. Nat. Med. 13, 1324-1332 (2007
202. Subramaniam N., et al. Metformin-mediated BAMBI expression in hepatic stellate cells induces prosurvival Wnt/β catenin signaling. Cancer Prev. Res. 5, 553-561 (2012
203. Ogawa S., et al. Anti-PDGF B monoclonal antibody reduces liver fibrosis development. Hepatol. Res. 40, 1128-1141 (2010
204. Coulon S., et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793-19805 (2013
205. Ardi, V. C., Kupriyanova, T. A., Deryugina, E. I., & Quigley, J. P. Human neutrophils uniquely release TIMP-free MMP 9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl Acad. Sci. USA 104, 20262-20267 (2007
206. Purcell B. P., et al. Injectable and bioresponsive hydrogels for on demand matrix metalloproteinase inhibition. Nat. Mater. 13, 653-661 (2014
207. Bystrom J., et al. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. Blood 112, 4117-4127 (2008
208. Ramachandran, P., et al. Differential Ly 6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis. Proc. Natl Acad. Sci. USA 109, E3186-E3195 (2012
209. Hellstr?m M., et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell. Biol. 153, 543-553 (2001
210. Lindblom P., et al. Endothelial PDGF B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev. 17, 1835-1840 (2003
211. Lindahl, P., Johansson, B. R., Leveen, P., & Betsholtz, C. Pericyte loss and microaneurysm formation in PDGF B deficient mice. Science 277, 242-245 (1997
212. Kelly-Goss, M. R., Sweat, R. S., Stapor, P. C., Peirce, S. M., & Murfee, W. L. Targeting pericytes for angiogenic therapies. Microcirculation 21, 345-357 (2014
213. Ayres-Sander, C. E., et al. Transendothelial migration enables subsequent transmigration of neutrophils through underlying pericytes. PLoS ONE 8, e60025 (2013
214. Ren S., et al. LRP 6 is a coreceptor for multiple fibrogenic signaling pathways in pericytes and myofibroblasts that are inhibited by DKK 1. Proc. Natl Acad. Sci. USA 110, 1440-1445 (2013
215. Humphreys B. D., et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010
216. Lee W. Y., et al. An intravascular immune response to Borrelia burgdorferi involves Kupffer cells and iNKT cells. Nat. Immunol. 11, 295-302 (2010
217. Chintalgattu V., et al. Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity. Sci. Transl. Med. 5, 187ra69 (2013
218. Ehnman M., et al. Distinct effects of ligand-induced PDGFRα and PDGFRβ signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res. 73, 2139-2149 (2013
219. Ruan J., et al. Imatinin disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 121, 5192-5202 (2013
220. Reck, M., et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143-155 (2014
221. Purow, B. Notch inhibition as a promising new approach to cancer therapy. Adv. Exp. Med. Biol. 727, 305-319 (2012
222. Sun, L., et al. Discovery of 5-[5 fluoro 2 oxo 1, 2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl 1H pyrrole 3 carboxylic acid (2 diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J. Med. Chem. 46, 1116-1119 (2003
223. Roberts, W. G., et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP 673, 451. Cancer Res. 65, 957-966 (2005
224. Wilhelm S. M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109 (2004
225. Laird A. D., et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 60, 4152-4160 (2000
226. Pan, B. S., et al. MK 2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c Met receptor. Cancer Res. 70, 1524-1533 (2010
227. Albert, D. H., et al. Preclinical activity of ABT 869, a multitargeted receptor tyrosine kinase inhibitor. Mol. Can. Therap. 5, 995-1006 (2006
228. Hu Lowe, D. D., et al. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG 013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin. Cancer Res. 14, 7272-7283 (2008
229. Buchdunger E., et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-Tyrosine kinase inhibitor of the 2 phenylaminopyrimidine class. Proc. Natl Acad. Sci. USA 92, 2558-2562 (1995
230. Heinrich, M. C., et al. Inhibition of c KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 96, 925-932 (2000
231. Heinrich M. C., et al. Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res. 18, 4375-4384 (2012
232. Trudel, S., et al. CHIR 258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4; 14) multiple myeloma. Blood 105, 2941-2948 (2005
233. Hilberg F., et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 68, 4774-4782 (2008
234. Pyonteck S. M., et al. CSF 1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 19, 1264-1272 (2013
235. Qian B. Z., et al. CCL2 recruits inflammatory monocytes to facilitate breast-Tumour metastasis. Nature 475, 222-225 (2011
236. Allavena P., et al. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-ssociated effectors and of major histocompatibility antigen expression on tumor cells. Cancer Res. 50, 7318-7323 (1990
237. Krieg, A. M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5, 471-484 (2006
238. Sun, Z., Yao, Z., Liu, S., Tang, H., & Yan, X. An oligonucleotide decoy for Stat3 activates the immune response of macrophages to breast cancer. Immunobiology 211, 199-209 (2006
239. Hemmi H., et al. Small anti-viral compounds activate the immune cells via the TLR7 MyD88 dependent signaling pathway. Nat. Immunol. 3, 196-200 (2002
240. Rolny C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 19, 31-44 (2011
241. Freemerman A. J., et al. Metabolic reprogramming of macrophages: glucose transporter 1 (GLUT1)-mediated glucose metabolism drives a proinflammatory phenotype. J. Biol. Chem. 289, 7884-7896 (2014
242. Beatty G. L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616 (2011
243. Odegaard J. I., et al. Macrophage-specific PPAR? controls alternative activation and improves insulin resistance. Nature 447, 1116-1120 (2007
244. Lutgens E., et al. Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J. Exp. Med. 207, 391-404 (2010
245. Kurowska-Stolarska M., et al. IL 33 amplifies the polarization of alternatively activated macrophages that contribute to airway inflammation. J. Immunol. 183, 6469-6499 (2009
246. Germano G., et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 70, 2235-2244 (2010